The Need to Address AMR Burden During COVID-19 Times
09 July 2020
As per the World Health Organisation, only a small proportion of COVID-19 patients need antibiotics to treat subsequent bacterial infections and has issued guidance not to provide antibiotic treatment to patients with mild COVID-19 illness. However, people are consuming high doses of antibiotics as a precautionary measure when they feel symptoms like fever, cold and cough, without acknowledging that this could lead to antimicrobial resistance (AMR).
Further reading: ET Health World
Author(s): Patrick R Murray
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
